SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2,106.75 |
| Enterprise Value ($M) | 1,995.91 |
| Book Value ($M) | 101.69 |
| Book Value / Share | 1.87 |
| Price / Book | 20.72 |
| NCAV ($M) | 98.16 |
| NCAV / Share | 1.80 |
| Price / NCAV | 21.46 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.62 |
| Return on Assets (ROA) | -0.46 |
| Return on Equity (ROE) | -0.61 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.71 |
| Current Ratio | 7.71 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 172.02 |
| Assets | 175.55 |
| Liabilities | 73.86 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -102.01 |
| Net Income | -95.99 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -92.18 |
| Cash from Investing | -39.43 |
| Cash from Financing | 133.54 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Sofinnova Venture Partners X, L.P. | 5.40 | -22.87 | |
| 13G/A | Kynam Capital Management, LP | 8.22 | 159.06 | |
| 13G/A | Ares Trading S.A. | 3.60 | 0.00 | |
| 13G/A | Commodore Capital Lp | 11.30 | 113.49 | |
| 13G/A | Citadel Advisors Llc | 0.10 | ||
| 13G | Woodline Partners LP | 2.20 | ||
| 13G/A | Fmr Llc | 6.24 | -16.12 | |
| 13D/A | Longitude Capital Partners IV, LLC | 9.80 | 0.19 | |
| 13G | BlackRock Inc. | 6.20 | ||
| 13D/A | Carlyle Group Inc. | 4.20 | -22.51 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 149,450 | 279,458 | 53.48 | |
| 112,967 | 298,132 | 37.89 | |
| 140,656 | 291,484 | 48.26 | |
| 220,565 | 372,094 | 59.28 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| URGN – UroGen Pharma Ltd. | VAXX – Vaxxinity, Inc. |
| VCEL – Vericel Corporation | VNDA – Vanda Pharmaceuticals Inc. |
| VRCA – Verrica Pharmaceuticals Inc. |
Financial data and stock pages provided by
Fintel.io